MAULDIN, SC / ACCESSWIRE / October 23, 2024 / Xcelerate, Inc. (OTCQB:XCRT) today announced that ESN Group, Inc., a subsidiary of Xcelerate, Inc., has launched its’ Ceramedx Brand Tik Tok Skincare Campaign, which shall occur during November and December 2024.
Jay Kline, President of ESN Group commented “This campaign will be launched in parallel with an enhanced social media/digital marketing launch. The goal is to expand brand awareness, including the unique differentiators vs. traditional synthetic brands. Personal Care industry studies indicate that the trend for products that focus on maintaining a healthy skin barrier remains paramount in the Skincare segment. According to industry research firms including Wonnda, Mintel, Euromonitor and Numerator, brands introducing innovative products designed to repair and restore compromised skin are a top priority for consumers from the very young to the more mature. Two ingredients, ceramides and seaweed, continue to attract consumer attention. Our Ceramedx brand is built around its natural plant-based ceramide technology. Our Earth Natural Beauty brand has products which contain seaweed as its key ingredient”.
“This Tik Tok launch follows a successful Ceramedx promotion in early October targeting the Army & Air Force Exchange Membership. Business at the Exchange doubled in growth during the 1 week promotional window. We are preparing to run a month-long pre-Holiday promotion during December with the Army & Air Force Exchange” continued Mr. Kline.
Investors and shareholders are encouraged to stay updated on the latest developments by visiting the Company’s website at https://xcelerate.global.
ABOUT XCELERATE INC.
In May 2020, Xcelerate commenced implementation of a new business plan that encompasses two separate but related businesses within the medical industry, including (i) owning and licensing the rights to various forms of medical equipment and portfolio of patents, patents pending and technology licenses and (ii) development of virtual health technology to assist patients in developing countries obtain medical care by extending the reach of physicians through the use of that technology. For more information visit www.xcelerate.global or contact us at 854-900-2020 or email info@xcelerate.global.
SAFE HARBOR
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company’s financing plans; (ii) trends affecting the Company’s financial condition or results of operations; (iii) the Company’s growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.
SOURCE: Xcelerate
View the original press release on accesswire.com
HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…
This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…
Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…
SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…